Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
C4 Therapeutics, Inc. | Chief Financial Officer | Common Stock | 32.7K | $213K | $6.52 | Aug 30, 2023 | Direct |
C4 Therapeutics, Inc. | Chief Financial Officer | Performance Restricted Stock Units | 16.5K | $105K | $6.36 | Aug 30, 2023 | Direct |
ImmunoGen, Inc. | SVP, CFO AND PFO | Restricted Stock Unit | 0 | $0 | $29.30 | Feb 12, 2024 | Direct |
ImmunoGen, Inc. | SVP, CFO AND PFO | Stock Option (Right to Buy) | 0 | $0 | $4.56 | Feb 12, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
IMGN | ImmunoGen, Inc. | Feb 12, 2024 | 3 | $0 | 4 | Feb 12, 2024 | SVP, CFO AND PFO |
IMGN | ImmunoGen, Inc. | Feb 1, 2024 | 1 | $0 | 4 | Feb 5, 2024 | SVP, CFO AND PFO |
IMGN | ImmunoGen, Inc. | Sep 18, 2023 | 2 | $0 | 4 | Sep 19, 2023 | SVP, CFO AND PFO |
IMGN | ImmunoGen, Inc. | Sep 18, 2023 | 0 | $0 | 3 | Sep 19, 2023 | SVP, CFO and PFO |
CCCC | C4 Therapeutics, Inc. | Aug 30, 2023 | 3 | -$1.94K | 4 | Aug 31, 2023 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Feb 13, 2023 | 2 | $0 | 4 | Feb 15, 2023 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Jan 30, 2023 | 3 | -$10.1K | 4 | Feb 1, 2023 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | May 26, 2022 | 1 | -$7.73K | 4/A | Jun 14, 2022 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | May 25, 2022 | 2 | $0 | 4 | May 27, 2022 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Feb 14, 2022 | 2 | $0 | 4 | Feb 16, 2022 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Jun 21, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Jun 21, 2021 | 0 | $0 | 3 | Jun 21, 2021 | Chief Financial Officer |